NASDAQ:MLYS
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. reported net income of −$154.7M in fiscal 2025. Free cash flow was −$142.4M, and the diluted share count rose 39.4%.Summary generated from Mineralys Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−36.9%
Debt / equityn/a
Free cash flow−$142.4M
FCF marginn/a
Share count change+39.4%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a |
| Operating income | −31 | −85 | −192 | −171 |
| Net income | −30 | −72 | −178 | −155 |
| Free cash flow | n/a | −81 | −166 | −142 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Sep 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KOther events
Jun 3, 2026 - 8-KEntry into a material agreement
Jun 3, 2026 - 8-KResults of a shareholder vote
May 22, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026